Kornimate/medical-research-clean huggingface dataset:
ovarian clear cell adenocarcinoma review

Conditions: Ovarian Cysts

Summary: clear cell carcinoma comprises 5-10% of surface epithelial ovarian cancers, and about 30-40% of the patients with clear cell carcinoma are diagnosed in the advanced stage. the investigators studied the response to chemotherapy and survival for either paclitaxel-platinum based chemotherapy or conventional platinum-based chemotherapy among all stages clear cell ovarian carcinoma. prognostic factors for survival among the patients with pure, advanced, clear cell ovarian carcinoma were also evaluated.

1. several authors have reported frequent admixtures of clear cell ovarian carcinoma with serous, mucinous, and endometrioid tumors. however, few papers addressed the difference in response to chemotherapy and survival between patients with pure and mixed-type advanced clear cell carcinoma. 2. recent trends in the clinical management of advanced ovarian cancer include increased attention to maximal cytoreduction and general acceptance of paclitaxel-platinum-based adjuvant chemotherapy. 3. the introduction of paclitaxel markedly changed the postoperative management of ovarian cancer patients, but the results and value of these newer efforts and therapies applied to clear cell carcinoma are as yet undetermined. 4. today, paclitaxel-platinum-based chemotherapy is becoming the standard regimen for ovarian cancer worldwide. previous research suggests a potential benefit of paclitaxel plus carboplatin regimens for stage i clear cell carcinoma. however, few papers specifically addressed the efficacy of paclitaxel-platinum-based chemotherapy for advanced clear cell carcinoma because clear cell carcinoma occurs only rarely in western countries.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of ovarian clear cell carcinoma exclusion criteria: * not undergo operation

Keywords: ovarian cancer clear cell carcinoma paclitaxel-platinum chemotherapy response to chemotherapy survival of clear cell ovarian carcinoma prognostic factors
acute effects of thc in older adult

Conditions: Age-related Cognitive Decline

Summary: the primary objective of this study is to determine if increasing age confers greater vulnerability to the acute a) cognitive (e.g., memory, attention, psychomotor function), b) subjective (e.g., anxiogenic and rewarding effects), and c) cardiovascular (heart rate and blood pressure), effects of thc in adults \> 21 years old. the secondary aims of the study are to explore age-related acute effects of thc on electrophysiological indices of information processing (e.g., auditory steady-state response (assr), oddball paradigm \[p300\], and resting state cortical noise) and to determine age-related differences in the metabolism of thc. it is hypothesized that increasing age will confer greater vulnerability to thc-induced cognitive impairments, anxiogenic effects, and cardiovascular effects but are less vulnerability to its rewarding effects. increasing age will confer greater vulnerability to thc-induced deficits in electrophysiological indices of information processing including.


Eligibility criteria:
* at least one lifetime use of cannabis and/or thc in the past ten years * negative urine screen for illicit substance use * no other illicit substance use during the past three months * not nicotine dependent (5 cigarettes per day; score of 3 on the fagerstrom test for nicotine dependence) * alcohol use ≤ 7 drinks/week in women and 14 in men * no current or past serious mental illness (e.g., schizophrenia, bipolar and related disorders, etc.) diagnosed with the use of the diagnostic and statistical manual of mental disorders (dsm-5) * no family history of psychosis * no history of significant medical or neurological disease per pi discretion * bmi ≤ 32 * high school education or greater * no positive pregnancy test and/or lactation * english speaking
dex vs sevo in congenital heart surgery

Conditions: Heart Defects, Congenital

Summary: anesthesia-related neurotoxicity in the developing brain is still a concern although evidence in humans is debatable. moreover, it is unclear whether repeated and/or prolonged exposures are harmless and whether their effects are more pronounced in newborns and infants with brains more vulnerable to injury. one such specific group of patients is children with congenital heart disease (chd). nearly, half of the school-age survivors with chd exhibit neurodevelopmental symptoms. it is thus important to elucidate whether any plausible neurotoxicity of the commonly used anesthetic agents can be observed in this population, and whether specific neuroprotective strategies can be demonstrated within the frame of a randomized controlled trial (rct). animal data have shown that dexmedetomidine (dex) induces neuroprotective effects only at well-adjusted doses. one major issue with trials of anesthetic neurotoxicity is the latency between the conduct of these studies and the assessment of neurodevelopmental outcome. in contrast, the use of biomarkers of neuronal injury could be extremely valuable. serum neurofilament light (nfl) has been shown to be a sensitive and specific marker of neuronal injury and is associated with neurologic outcome of children with various pathologies. the investigators hypothesize that in congenital heart surgery, use of dex as main anesthetic agent in conjunction with low dose sevoflurane results in less release of serum nfl and is thus potentially less neurotoxic compared to the current standard of care. the hypothesis is tested with a rct including patients between 0 - 3y undergoing surgery with cardiopulmonary bypass. to avoid any neurotoxicity due to anesthetic overdose, intraoperative burst suppression will be avoided. in addition to postoperative comparison of serum nfl, postoperative electroencephalogram and neurodevelopmental outcome of both groups will be compared taking into consideration the genetic background.


Eligibility criteria:
inclusion criteria: * patients up to 3 years * must undergo cardiac surgery with cpb exclusion criteria: * preoperative chronic kidney disease (glomerular filtration rate of less than 30 ml/min per 1.73m2 for greater than 3 months) * preoperative cerebral hemorrhage, stroke or * preoperative seizures * abnormal preoperative cerebral ultrasound * preoperative extracorporeal life support * preoperative sedated and intubated patients * preterm newborns (\< 32 w gestational age) * newborns weighing \< 2 kg * patients with williams-beuren syndrome.
effect of daily short message system (sms) reminders on medication adherence to oral antipsychotics in patients with schizophrenia

Conditions: Schizophrenia

Summary: this study is a 6-month, multicenter, randomized study to assess the effect of daily sms reminders sent during 3 months in the adherence to oral antipsychotic treatment in stabilized outpatients with schizophrenia.


Eligibility criteria:
inclusion criteria: * male or female patients older than 18 years * with a diagnosis of schizophrenia (dsm-iv tr criteria) * stabilized out-patients * under oral antipsychotic monotherapy exclusion criteria: * administration of a depot antipsychotic drug * suicide risk

Keywords: schizophrenia therapeutic adherence short message system mobile phone
impact of serum progesterone levels on the day of β-hcg test in artificial cycles on the ongoing pregnancy rate.

Conditions: Infertility, Female

Summary: prospective cohort multicentric study including infertile patients undergoing a pregnancy test on βhcg day (around et +11), after an et in the context of an artificial cycle and receiving lps with vaginal natural progesterone following the clinical practice in ivi rma (spain).

the investigation team have already demonstrated that serum progesterone levels measured on the et day in artificial cycles are related to pregnancy outcome. in this line, this problem can be countteracted after supplementation with an additional source of external progesterone, achieving similar ongoing pregnancy and live birth rates in women with serum progesterone levels below and above the threshold point determined on the et day. despite this, it has been observed apparent differences on the maintenance of pregnancy in patients with a positive pregnancy test according to their serum progesterone levels measured on day et+11, which is the same day in which we perform the pregnancy test. these differences seem to be originated due to later higher clinical miscarriage rates in patients with lower serum progesterone levels on day et+11, despite their positive pregnancy test. this fact may be due to patientes low serum progesterone levels, insufficient to maintain an ongoing pregnancy. taking this into account, this study aim to confirm that serum progesterone levels on βhcg day are indeed related to final pregnancy outcome and to evaluate if there is any cut-off point of serum progesterone levels, as we have previously found on the et day.

Eligibility criteria:
inclusion criteria: * the subject must provide written informed consent prior to any study related procedures * women ≤50 years old * bmi ≤ 35 kg/m2 * adequate endometrial thickness (\>6.5mm) and pattern (triple a structure) in the proliferative phase exclusion criteria: * uterine pathology, adnexal pathology * systemic diseases

Keywords: serum progesterone late lueteal phase ongoing pregnancy rate artificial cycle luteal phase support embryo transfer
the efficacy and safety of risperidone in the treatment of adolescents with schizophrenia

Conditions: Schizophrenia

Summary: a clinical study to compare the safety and effectiveness of two different dose ranges of risperidone solution in the treatment of adolescents with a diagnosis of schizophrenia.

this is a clinical study of an investigational drug called risperidone in the treatment of schizophrenia in adolescents. initially children (age 2 to 12 yrs) and schizophreniform subjects were also allowed but excluded following protocol amendment. the study will include approximately 260 patients aged 13 to 17 years with a diagnosis of schizophrenia. subjects will be randomly assigned to one of two groups on enrollment and will be given risperidone as an oral solution each day for 8 weeks at doses within one of two dose different ranges, according to the assigned study group. initially the two dose range were 0.15-0.4 mg/day and 1.5-4mg/day but were changed in protocol amendment to evaluate the maximum tolerated dose with a minimum of 3.5mg/day and maximum of 6mg/day (resp. 0.35 and 0.6mg/day in low dose treatment arm) risperidone lower dose (0.35-0.6 mg/day \[subjects \>=50kg\] or 0.007-0.012 mg/kg/day \[subjects \ =50 kg\] or 0.07-0.12 mg/kg/day \[subjects \<50 kg\]) as 1 mg/ml oral solution for 8 weeks. daily dose can be given all at once or through 2 administrations (in morning and evening); the dose is increased based on efficacy and tolerability.

Eligibility criteria:
inclusion criteria: * subjects will be eligible for study enrollment if they: are adolescents between the ages of 13 and 17 years * have a confirmed diagnosis of schizophrenia and are suffering from an acute episode * provide their assent and parental informed consent to participate * are otherwise relatively healthy on the basis of a medical and physical examination * and are able to be in-patients for approximately 2 weeks. exclusion criteria: * subjects will be excluded from the study if they: meet the criteria for psychiatric disorders other than schizophrenia * have moderate or severe mental retardation * fail to respond to treatment with at least two typical or atypical antipsychotics * have a history of substance dependence within the 3 months before screening * are considered at risk for suicidal or violent behavior * have a seizure disorder * have a history of neuroleptic malignant syndrome, similar encephalopathic syndrome, or tardive dyskinesia * or receive prohibited medication within a specified period before screening.

Keywords: adolescents schizophrenia risperidone
the use of pressure sensors in functional assessment and treatment of low back pain patients

Conditions: Chronic Low-back Pain

Summary: the dissertation will focus on the possibilities of using pressure sensors during physiotherapy care. a single-blind randomized study will be conducted on a sample of at least 40 probands of working age with chronic lbp in the age range of 30-65 years. the following exclusive criteria are established: signs of serious spinal pathology (red flags), severe musculoskeletal trauma in the last year, vestibular, visual or neurological dysfunction affecting stability, ongoing pregnancy or breastfeeding, acute respiratory disease, cognitive dysfunction leading to misunderstanding of instructions and severe cardiac or internal disease. inclusive and exclusive criteria will be evaluated by a rehabilitation doctor during a comprehensive examination before the start of therapy. all probands will undergo six-week outpatient therapy once a week. the intervention group will be equipped with an ohmtrak device for home self-therapy and instructed in its correct use at least 5 times a week. the control group will receive identical outpatient therapy and instruction in self-therapy, except they will not have access to the ohmtrak device. before the start and at the end of the six-week therapy, all probands will be blindly evaluated for the quality of activation and use of intra-abdominal pressure with the dns brace device. at the same time, the oswestry disability index questionnaire will be used to subjectively evaluate the probands before and after a series of therapies. the aim of the study is to demonstrate the possibility of using pressure sensors to improve the effect of physiotherapy.


Eligibility criteria:
inclusion criteria: * patient with chronic low back pain * age range of 30-65 years. exclusion criteria: * signs of serious spinal pathology (red flags) * severe musculoskeletal trauma in the last year * vestibular, visual or neurological dysfunction affecting stability * ongoing pregnancy or breastfeeding * acute respiratory disease * cognitive dysfunction leading to misunderstanding of instructions * severe cardiac or internal disease

Keywords: intra-abdominal pressure biofeedback dynamometry
a study of prevalence of egfr mutations in participants with nsclc

Conditions: Non-Small Cell Lung Cancer

Summary: this is a non-interventional, local, multicenter, cross-sectional study to determine the prevalence of epidermal growth factor receptor (egfr) mutations in participants diagnosed with non-squamous non-small cell lung cancer (nsclc).


Eligibility criteria:
inclusion criteria: * informed consent form signature * jordanian male and female participants greater than or equal to (\>=) 18 years of age * histologically confirmed nsclc * not participating in a study that involves an investigational agent within 30 days prior to enrollment exclusion criteria: * other primary malignancy * fine needle aspiration samples

Keywords: non-small cell lung cancer (nsclc)
fl-101 in surgically resectable non-small cell lung cancer

Conditions: Non-Small Cell Lung Cancer

Summary: phase 2 trial to study fl-101 alone or in combination with nivolumab in patients who have surgically resectable non-small cell lung cancer.

a 2-cohort, phase 2, multicenter, parallel-design trial that will study patients with surgically resectable, stages i-iiia, non-small cell lung cancer (nsclc) . the clinical study will focus on whether fl-101 has direct anti-tumor activity when given alone prior to surgery, and if fl-101 improves the anti-tumor response when given in combination with nivolumab prior to surgery.

Eligibility criteria:
inclusion criteria: 1. previously untreated and pathologically confirmed, surgically resectable stage ia3, ib, ii, or iiia nsclc of squamous or non-squamous histology. 2. ≥1 radiologically measurable tumor \>2cm in diameter. 3. smoking history ≥10 pack years. 4. available tissue block for analysis from a core needle biopsy(or similar sample) 5. high-sensitivity c-reactive protein (hscrp) level ≥2 mg/l exclusion criteria: 1. any prior exposure to chemotherapy, radiotherapy or systemic anti-cancer therapy (e.g., monoclonal antibody therapy) for lung cancer. 2. malignancies other than nsclc within 2 years prior to cycle 1, day 1, with the exception of those with a negligible risk of metastasis or death and with expected curative outcome 3. currently participating in, or has participated in, a trial of an investigational agent within 4 weeks prior to the first dose of study treatment or 5 half-lives, whichever is longer and with recovery of clinically significant toxicities from that therapy. 4. tumors known to express driver mutations of the egfr or alk pathways. 5. known severe hypersensitivity (grade ≥3) to fl-101, its active substance, or any of its excipients 6. known history of human immunodeficiency virus or active hepatitis b or hepatitis c infection additional exclusion criteria for patients with stage ii and iii disease 1. prior treatment with anti-pd-1, anti-ctla-4, or anti-pd-l1 therapeutic antibody or pathway-targeting agents 2. treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \[anti-tnf\] agents) within 2 weeks prior to cycle 1, day 1 3. known severe hypersensitivity (grade ≥3) to nivolumab or chemotherapy agents or to any of their excipients.

Keywords: surgically resectable nsclc nivolumab fl-101 placebo
inflammatory signature of human chorionic cells

Conditions: Pregnancy

Summary: the purpose of this study is to identify molecules produced specifically by the cells from the chorionic membranes of the materno-fetal interface ("the water bag") sign for the activation of preterm labor.

· background during human gestation, fetal membranes (the "water bag") encompass the amnion, facing the amniotic cavity, and the chorion, lining the maternal decidua and comprising trophoblast cells. membranes usually remain intact until their spontaneous rupture, close to the first stage of labor at term. often seen as a simple inert shell, with a role of "airbag" for the developing fetus, the membranes provide yet a large surface of interaction between maternal and fetal tissues and function as a transient endocrine organ with immune properties. indeed human parturition is tightly correlated with hormonal changes at the maternal-fetal interface during pregnancy, that may control cell interactions and chorio-decidua remodeling, the amnion remaining usually intact until the final break. precocious remodeling may lead to a premature onset of labor, associated or not with premature rupture of membrane whether the cause is infectious or not. a better understanding of this membrane remodeling may thus offer new avenues to define biomarkers of preterm labor. hereof, the fact that the mother-to-be accepts and keeps the fetus for months within her womb has long being seen as an enigma, since the fetus is a semi-allograft, half of his genome being of paternal, thus of foreign, origin. this apparent paradox was deciphered by the demonstration of the set-up of an immunotolerance at the site of implantation through the education of maternal immune cells (natural killer and t cells) by the fetal trophoblast. this immunotolerance is normally maintained throughout pregnancy, and some recurrent spontaneous miscarriages have been shown to be due to the loss of this immunotolerance, which activates the rejection of the semi-allograft. in this regard, remodeled fetal membranes overlying the cervix may discharge signals that could be detectable in cervicovaginal fluids and serve as biomarkers of the imminence of delivery. such information on delivery timing may be of great importance for an adequate prediction that would change drastically the management of threatening preterm delivery. · current proposal the objective of this study is to characterize the fetal and maternal cells in the chorio-decidua during the remodeling of the membranes using our well-established cell model (hervé et al. 2008, j immunol).

Eligibility criteria:
inclusion criteria: * \>18y old * singleton * normal pregnancy without complication * \>37 weeks of gestation exclusion criteria: * minor * without health insurance * inflammatory disorders (diabetes, twin, autoimmune disesses, etc) * infection hiv, hepatitis

Keywords: pregnancy remodelling extracellular matrix biomarkers
a prospective study frailty for esophagectomy and lung resection in thoracic surgery

Conditions: Thoracic; Thoracic Neoplasm; Lung Cancer; Esophageal Cancer; Surgery--Complications; Surgery; Sarcopenia; Malnutrition; Frail Elderly Syndrome

Summary: the purpose of this study is to develop an all-encompassing frailty model using laboratory and functional studies. a frailty model will help us determine prior to surgery who will require rehabilitation and skilled nursing needs beyond discharge. this model will also help us determine who will likely be readmitted and why they will be readmitted. understanding these things can help us prevent some of them from occurring in the future.

frailty is a widely accepted but poorly defined physical condition that has been shown to be an independent predictor of surgical morbidity and direct discharge to skilled nursing facility (snf). attempts have been made to study frailty in surgical patients by employing models designed for the general population. despite the attempts of studying frailty in general surgery patients, no study has designed a model comprised of objective metrics for general thoracic surgery patients. the purpose of this study is to better understand frailty in the context of thoracic surgery patients and to develop an objective model of this nebulous variable. it is hoped that standard, simple, functional and laboratory data can be used to construct the model with the goal being to determine the impact of frailty on outcome for patients undergoing esophagectomy, lobectomy, or pneumonectomy. if a preoperative frailty index can be developed and demonstrated to predict outcome, this scoring system may allow care teams to predict post-operative complications, icu and hospital recidivism, and early mortality, and possibly allow for much earlier preparation for unfavorable outcomes.

Eligibility criteria:
inclusion criteria: * all patients \>18 years old who are undergoing pneumonectomy, lobectomy or esophagectomy with a cancer diagnosis over a 1-year enrollment. exclusion criteria: * patients who are unable to sign a consent.
effect of black mulberry lollipop on prevention of oral mucositis in children

Conditions: Oral Mucositis

Summary: the effect of black mulberry lollipop and sodium bicarbonate used in oral care on prevention of oral mucositis among children receiving chemotherapy due to cancer

the study was conducted experimentally to determine the effect of black mulberry lollipop and sodium bicarbonate used in oral care on prevention of oral mucositis in children followed up due to the diagnosis of cancer. sodium bicarbonate and black mulberry treatment were compared to prevent oral mucositis in 69 children receiving chemotherapy due to cancer. while 35 children were assigned to the experimental group (sodium bicarbonate + black mulberry lollipop application), 34 were assigned to the control group (sodium bicarbonate application).

Eligibility criteria:
inclusion criteria: * being in the age group of 3-18 years * being hospitalised for chemotherapy treatment * not having oral mucositis * no using another method to protect oral mucosa during the study period * not having the history of black mulberry (similar fruit berries, blackberries, etc.) allergy * not having intolerance to cold exclusion criteria: -not having food in mouth

Keywords: keywords: chemotherapy, oral mucositis, black mulberry, bicarbonate, paediatric oncology